Haloperidol (CED0001620)

Haloperidol is an exogenous solid with the formula C21H23ClFNO2 and an average molecular weight of 375.86 g/mol. Haloperidol belongs to the carbonyl compounds, a subclass of organooxygen compounds within the organic compounds. This biological drug acts as a first generation antipsychotic, dopaminergic antagonist, serotonergic antagonist, antiemetic, and antidyskinesia agent (PMC6415270). It is used as a treatment for schizophrenia (PMC7254783) and delirium (PMC12276463, PMC5351776, PMC7390577), with a noted therapeutic effect on delirium (PMC5351776). Additionally, the compound is associated with a decrease in bradycardia (PMC6180974). Haloperidol targets 30 recorded proteins, including the D(2) dopamine receptor (DRD2), D(1A) dopamine receptor (DRD1), D(3) dopamine receptor (DRD3), the antagonist of 5-hydroxytryptamine receptor 2A (HTR2A), Glutamate receptor ionotropic NMDA 2B (GRIN2B), Peroxisome proliferator-activated receptor delta (PPARD), and Nuclear receptor subfamily 1 group I member 2 (NR1I2), among 23 others. Its effect on the central nervous system is thought to be associated with an increased turnover rate of brain dopamine and the competitive blockade of postsynaptic dopamine D2 receptors in the mesolimbic dopaminergic system, though the precise mechanism producing its therapeutic effects is not known. The compound is found in 43 recorded sources, including antipsychotics within healthcare, pharmaceuticals, and veterinary products; food processing, meat processing, and fermentation processes for beer; household cleaning and consumer products such as soap detergents, perfumes within detergents and soaps, and smoking requisites; building and construction materials; and electrical and electronic equipment. Recorded exposure routes include oral and intramuscular administration.